Cloxacillin

證據等級: L5

預測適應症: 10 個

Cloxacillin: From MSSA Infections to Bacterial Arthritis

One-Sentence Summary

Cloxacillin is an isoxazolyl penicillin antibiotic with well-established bactericidal activity against methicillin-susceptible Staphylococcus aureus (MSSA), clinically used for skin, soft tissue, and bone-and-joint infections — though not currently registered in Singapore. Among 10 TxGNN-predicted indications, bacterial arthritis emerges as the most evidence-supported candidate, with 2 clinical trials and 20 publications identified, carrying an L3 evidence rating and a "Proceed with Guardrails" recommendation. Note: The top TxGNN score prediction (chronic rhinosinusitis, 98.3%) has no supporting clinical evidence and a "Hold" decision; bacterial arthritis (rank 5, score 97.7%) is selected as the focus of this report due to its superior mechanistic plausibility and evidence base.

Quick Overview

Item	Content
Original Indication	MSSA infections (skin, soft tissue, bone and joint) — not registered in Singapore
Predicted New Indication	Bacterial Arthritis (MSSA Septic Arthritis)
TxGNN Prediction Score	97.68%
Evidence Level	L3
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Cloxacillin belongs to the isoxazolyl penicillin subclass of beta-lactam antibiotics. Its primary mechanism involves irreversible inhibition of penicillin-binding proteins (PBPs), thereby disrupting bacterial cell wall synthesis and triggering cell lysis. Its key distinguishing feature — a side-chain modification that sterically blocks staphylococcal beta-lactamase — gives it selective, potent activity against MSSA while it remains inactive against MRSA and most Gram-negative organisms.

Staphylococcus aureus is the leading causative pathogen in septic (bacterial) arthritis, responsible for more than 50% of cases across epidemiological surveys in adults. The mechanistic link between Cloxacillin and bacterial arthritis is therefore direct, not inferential: the drug targets the predominant etiological agent at its site of infection. A 1999 pharmacokinetic study (PMID 10350394) confirmed that a single 2 g IV dose of Cloxacillin achieved satisfactory bactericidal concentrations in synovial fluid against MSSA isolates, validating tissue penetration to the target compartment. A 2016 murine study (PMID 26695535) further demonstrated that Cloxacillin suppressed clinical disease and downmodulated both local and systemic pro-inflammatory cytokines in SEC+ MSSA-induced experimental arthritis, establishing direct in-vivo proof of concept.

International clinical practice guidelines (IDSA, BSAC, ESCMID) already list antistaphylococcal penicillins — including Cloxacillin and its congener Flucloxacillin — as first-line therapy for MSSA-confirmed septic arthritis. The TxGNN model prediction therefore reflects a mechanistically grounded and guideline-recognized treatment role, making it a strong and actionable repurposing candidate despite the absence of a dedicated Cloxacillin-specific RCT for this indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04563325	Phase 4	Completed	180	Nationwide multicenter RCT in children with bone and joint infections (including septic arthritis) comparing oral-only antibiotics vs. initial IV followed by oral therapy; supports non-inferiority of oral antistaphylococcal regimens, providing an evidence framework for Cloxacillin-class drugs in pediatric osteoarticular infections
NCT04141787	Phase 4	Unknown	310	Randomized non-inferiority trial of ceftriaxone vs. standard of care (typically Cloxacillin/Flucloxacillin) for home IV therapy of deep-seated staphylococcal infections including bone and joint; Cloxacillin serves as the active comparator, indirectly confirming its standard-of-care role

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30772469	2019	Systematic Review	Int J Infect Dis	Comprehensive review of antibiotic tissue penetration into bone and synovial fluid vs. pathogen MICs; supports beta-lactams including Cloxacillin as pharmacokinetically suitable for osteoarticular infections
26695535	2016	Animal Study (in vivo)	Cellular Microbiology	Cloxacillin directly controlled SEC+ MSSA-induced experimental arthritis in mice, with significant downmodulation of local and systemic pro-inflammatory cytokines; key direct proof-of-concept study
27455444	2016	Multicenter Observational	Pediatr Infect Dis J	Spanish multicenter study of acute osteoarticular infections in children; characterises microbiological spectrum (S. aureus predominant) and real-world antibiotic management patterns
25104892	2014	Retrospective Cohort	J Orthopaedics	Clinical and microbiological characteristics of primary septic arthritis at a university hospital; S. aureus predominance and treatment outcomes contextualize the need for targeted MSSA therapy
17576849	2007	Animal Study	Antimicrob Agents Chemother	In-vivo comparison of moxifloxacin, Cloxacillin, and vancomycin in a rabbit S. aureus arthritis model; no significant efficacy difference between regimens, supporting Cloxacillin as a reference standard
12010570	2002	Animal Study	Arthritis Research	Combined Cloxacillin + free-radical spin-trap (PBN) therapy reduced S. aureus-induced joint destruction in mice; suggests adjuvant anti-inflammatory strategies could complement Cloxacillin's antibacterial effect
29440371	2018	Experimental	Infect Immun	IL-15 inhibition combined with Cloxacillin reduced joint inflammation and bone erosion but not cartilage destruction in S. aureus arthritis; highlights residual host-inflammatory damage despite effective antibiotic therapy
24967110	2013	Prospective Study	ISRN Orthopedics	Bacterial spectrum and antibiotic sensitivity in pediatric septic arthritis in North India; S. aureus predominance and sensitivity profiles relevant to selecting Cloxacillin-class coverage
10350394	1999	Clinical PK Study	J Antimicrob Chemother	Cloxacillin 2 g IV achieved satisfactory bactericidal concentrations in synovial fluid against MSSA isolates; direct pharmacokinetic validation of joint-compartment drug penetration
2295180	1990	Retrospective Review	Clin Orthop Relat Res	Septic arthritis in elderly patients over a 10-year period; characterises clinical presentation, underlying comorbidities, and outcomes; contextualises treatment urgency and management complexity

Singapore Market Information

Cloxacillin is not currently registered in Singapore. No product authorisations are on record (total licences: 0). The drug is marketed in other regional jurisdictions — typically as oral capsules (250 mg, 500 mg) and IV/IM injectable formulations — under brand names such as Orbenin and various generics. A close congener, Flucloxacillin, is registered in several Asia-Pacific markets and may serve as a comparator for regulatory pathway discussions.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Cloxacillin is the established first-line antistaphylococcal agent for MSSA-confirmed septic arthritis in international clinical guidelines, with direct in-vivo evidence of efficacy in animal models (PMID 26695535, 17576849, 12010570), pharmacokinetically validated synovial fluid penetration (PMID 10350394), and multiple observational clinical studies confirming S. aureus as the dominant pathogen in bacterial arthritis. The evidence base is sufficient to justify a structured evaluation, provided key safety and regulatory gaps are addressed.

To proceed, the following is needed:

Retrieve full MOA data from DrugBank to complete mechanistic documentation for submission dossiers
Download and parse the package insert (TFDA or originator label) to populate contraindications, key warnings, and drug interaction data — currently blocking safety pre-screening (DG001)
Clarify the Singapore regulatory pathway: assess whether a new drug application, parallel import licence, or unregistered drug import authorisation (HSA Regulation 13) is required
Confirm availability and supply chain for IV and oral formulations through local importers or hospital pharmacy compounding
Compile supporting guideline citations (IDSA, BSAC, ESCMID) that explicitly recommend Cloxacillin or antistaphylococcal penicillins for MSSA septic arthritis, to serve as clinical justification documentation
Consider comparative data against Flucloxacillin (a registered congener in nearby markets) to inform substitutability arguments and simplify the regulatory case
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.